TrialClinical and experimental nephrology2015
The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial.
Satoru Muto et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
38 papers cite it
this paperpooled ittrialcites it